

# Investigational New Drug Application Profiling of CGK012, a PKC $\alpha$ activator, for treating age-related macular degeneration

AREZ



OPHTHALMOLOGY	Preclinical
Product Type	Intravitreal implant
Indication	Age-related macular degeneration (AMD) with <ul style="list-style-type: none"> <li>• non-responding to Anti-VEGF treatment</li> <li>• discomfort against frequent intravitreal injections of anti-VEGF treatment</li> <li>• side effects of anti-VEGF treatment</li> </ul>
Target	Pathogenic $\beta$ -catenin
MoA(Mechanism of Action)	As a PKC $\alpha$ activator, CGK012 <ul style="list-style-type: none"> <li>• promotes the phosphorylation and decomposition of pathogenic <math>\beta</math>-catenin</li> <li>• suppresses degeneration of retinal pigment epithelial cells</li> <li>• reduces inflammation</li> <li>• Suppresses choroidal neovascularization</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>• Sustained-release intravitreal implant with extended dosing intervals (3-6 months)</li> <li>• Price reduction using a small molecule synthesized by just one step</li> <li>• Combination therapy with other biologics</li> </ul>
Development Stage	Preclinical
Route of Administration	Intravitreal implantation